Our data support the evidence that PARP inhibition can be used as a viable therapeutic strategy against neurodegenerative disorders such as HD and offers further evidence for repurposing and extending the use of PARP inhibitors to non-oncological disorders. Here, PARP1 is linked to Huntington disease.